Cortexyme Stock Forecast, Price & News

+2.04 (+3.95 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume711,884 shs
Average Volume264,396 shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

Cortexyme logo

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.03 out of 5 stars

Medical Sector

1088th out of 2,097 stocks

Biological Products, Except Diagnostic Industry

149th out of 198 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

Is Cortexyme a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last twelve months. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cortexyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTX, but not buy additional shares or sell existing shares.
View analyst ratings for Cortexyme
or view top-rated stocks.

What stocks does MarketBeat like better than Cortexyme?

Wall Street analysts have given Cortexyme a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cortexyme wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Monday, August 16th 2021.
View our earnings forecast for Cortexyme

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) released its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by $0.08.
View Cortexyme's earnings history

How has Cortexyme's stock price been impacted by COVID-19 (Coronavirus)?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 45.1% and is now trading at $53.70.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CRTX?

6 brokerages have issued twelve-month target prices for Cortexyme's stock. Their forecasts range from $20.00 to $76.00. On average, they expect Cortexyme's stock price to reach $43.33 in the next twelve months. This suggests that the stock has a possible downside of 19.3%.
View analysts' price targets for Cortexyme
or view top-rated stocks among Wall Street analysts.

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 47, Pay $559.95k)
  • Dr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 65)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 54, Pay $479.7k)
  • Mr. Christopher P. Lowe, COO, CFO & Treasurer (Age 50)
  • Mr. Ted Monohon, Chief Accounting Officer (Age 55)
  • Ms. Caryn Gordon McDowell, Chief Legal & Admin. Officer and Corp. Sec. (Age 51)
  • Dr. Leslie J. Holsinger Ph.D., Exec. VP of R&D (Age 56)

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

When did Cortexyme IPO?

(CRTX) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by many different retail and institutional investors. Top institutional shareholders include EPIQ Capital Group LLC (12.37%), Capital International Investors (8.32%), BlackRock Inc. (4.61%), Pacific Heights Asset Management LLC (0.93%), Geode Capital Management LLC (0.88%) and Northern Trust Corp (0.57%). Company insiders that own Cortexyme stock include Casey Lynch, David Lamond, Epiq Capital Group, Llc and Leslie Holsinger.
View institutional ownership trends for Cortexyme

Which institutional investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Capital International Investors, Millennium Management LLC, Squarepoint Ops LLC, Goldman Sachs Group Inc., SG Americas Securities LLC, Cubist Systematic Strategies LLC, and Credit Suisse AG. Company insiders that have sold Cortexyme company stock in the last year include Casey Lynch, and Leslie Holsinger.
View insider buying and selling activity for Cortexyme
or view top insider-selling stocks.

Which institutional investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, Citigroup Inc., Hennion & Walsh Asset Management Inc., Pacific Heights Asset Management LLC, Rafferty Asset Management LLC, UBS Group AG, Geode Capital Management LLC, and ICONIQ Capital LLC. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, and Epiq Capital Group, Llc.
View insider buying and selling activity for Cortexyme
or or view top insider-buying stocks.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $53.70.

How much money does Cortexyme make?

Cortexyme has a market capitalization of $1.59 billion. The biopharmaceutical company earns $-76,850,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

How many employees does Cortexyme have?

Cortexyme employs 37 workers across the globe.

What is Cortexyme's official website?

The official website for Cortexyme is

Where are Cortexyme's headquarters?

Cortexyme is headquartered at 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at [email protected]

This page was last updated on 6/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.